About Us

HepQuant is a privately-held, early-stage combination drug and in-vitro diagnostic company with unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease.

The company’s products are investigational combination drug and in-vitro diagnostic devices and have not yet been evaluated or reviewed by the US Food and Drug Administration (FDA) for commercial sale. They are currently availaucd-amcble for investigational use via the FDA IDE application process.

HepQuant has partnered with a College of American Pathologists (CAP) / Clinical Laboratory Improvement Amendments (CLIA)certified laboratory.